MAKING THE RIGHT CHOICE: THE ROLE OF FITNESS STATUS IN THE MANAGEMENT OF FIRST-LINE TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS (CLL FITNESS STUDY)

EHA Library, Lydia Scarfò, 100733

EFFICACY OF PHOSPHATIDYLINOSITOL-3 KINASE INHIBITORS WITHDIVERSE ISOFORM SELECTIVITY PROFILES FOR INHIBITING THE SURVIVALOF CHRONIC LYMPHOCYTIC LEUKEMIA CELLS

EHA Library, Elisa Göckeritz, 100734

HEALTH RELATED QUALITY OF LIFE AND PATIENT REPORTED OUTCOMES OF OFATUMUMAB PLUS CHLORAMBUCIL VERSUS CHLORAMBUCIL MONOTHERAPY IN THE COMPLEMENT1 TRIAL

EHA Library, Stephanie Manson, 100735

GENOMIC PROFILE OF CHRONIC LYMPHOCYTIC LEUKEMIA IN KOREA:ETHNIC DIFFERENCE IN RECURRENT MUTATIONS IDENTIFIED BY TARGETED EXOME SEQUENCING

EHA Library, Jung-Ah Kim, 100736

CYTOTOXICITY FOR CHRONIC LYMPHOCYTIC LEUKEMIA CELLS OF THE CD37 ANTIBODY BI 836826 IN COMBINATION WITH CHEMOTHERAPEUTIC AGENTS OR PI3K INHIBITORS

EHA Library, Günter Krause, 100737

SOLUBLE CALRETICULIN PREDICTS FOR TIME TO FIRST TREATMENT OF PATIENTS WITH EARLY CHRONIC LYMPHOCYTIC LEUKEMIA.

EHA Library, Stefano Molica, 100738

INDIVIDUALIZED IMATINIB THERAPY BASED ON [C]MIN LEVELS MONITORING IN NEWLY DIAGNOSED CML PATIENTS RESULTED IN HIGHER MAJOR MOLECULAR RESPONSE RATES AT 12 MONTHS. RESULTS OF THE OPTIM-IMATINIB STUDY.

EHA Library, Philippe Rousselot, 100739

ATTEMPT TO EARLY DISCONTINUE DASATINIB FIRST LINE IN CHRONIC PHASE CML PATIENTS IN EARLY MOLECULAR RESPONSE AND INCLUDED IN THE PROSPECTIVE OPTIM-DASATINIB TRIAL.

EHA Library, Philippe Rousselot, 100740

REAL LIFE ANALYSIS OF CML MANAGEMENT DEMONSTRATES THAT SECOND-LINE THERAPY IS FREQUENTLY USED BUT IS PREMATURELY DISCONTINUED FOR INTOLERANCE: REPORT OF THE GROUPE QUÉBÉCOIS DE RECHERCHE EN LMC-NMP

EHA Library, Lambert Busque, 100741

CARDIOVASCULAR (CV) AND PULMONARY ADVERSE EVENTS (AES) IN PATIENTS (PTS) TREATED WITH BCR-ABL TYROSINE KINASE INHIBITORS (TKIS): UPDATED ANALYSIS FROM THE FDA ADVERSE EVENT REPORTING SYSTEM (FAERS)

EHA Library, Jorge Cortes, 100742

LONG-TERM BOSUTINIB IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) AFTER PRIOR IMATINIB FAILURE

EHA Library, Tim Brümmendorf, 100743

IMATINIB DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS ON PATIENTS IN CLINICAL PRACTICE

EHA Library, Giovanna Rege-Cambrin, 100744

VALIDATION OF A NEW PROGNOSTIC SCORE AIMED TO IDENTIFY THREE GROUPS WITH DIFFERENT PROBABILITIES OF DYING OF CHRONIC MYELOID LEUKAEMIA IN 1,120 PATIENTS WITH FIRST-LINE IMATINIB TREATMENT

EHA Library, Markus Pfirrmann, 100745

PROGRESSION OF CHRONIC PHASE CHRONIC MYELOID LEUKEMIA TO ADVANCED PHASE ON TKI THERAPY: A POPULATION BASED ANALYSIS FROM THE SWEDISH CML REGISTER

EHA Library, Stina Söderlund, 100746

INTERFERON-ΑLPHA REVISITED: INDIVIDUALIZED IMMUNE-MODULATION EASED UP SELECTION PRESSURE OF TKI ON BCR-ABL MUTATED CLONES AND IMPROVES MOLECULAR RESPONSE IN HIGH-RISK CML PATIENTS

EHA Library, Katerina MachovaPolakova, 100747

PREDICTION OF THE NUMBER OF CML– PATIENTS IN GERMANY: UP TO 20,000 ARE TO BE EXPECTED IN THE NEAR FUTURE

EHA Library, Michael Lauseker, 100748

KILLER IMMUNOGLOBULIN-LIKE RECEPTORS CAN PREDICT TKI TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA PATIENTS

EHA Library, Giovanni Caocci, 100749

AML1-EVI-1 FUSION GENE INHIBITED DIFFERENTIATION AND APOPTOSIS IN ZEBRAFISH MYELOPOIESIS

EHA Library, Lijing Shen, 100750

THE INFLUENCE OF SF3B1 MUTATIONS ON THE RESPONSIVENESS OF BLOOD CANCERS TO MOLECULAR THERAPEUTICS

EHA Library, Fabio Liberante, 100751

POLYMORPHISMS OF DNMTS AND FOLATE/METHIONINE METABOLISM GENES INFLUENCE DNA METHYLATION, GENETIC SUSCEPTIBILITY AND PROGNOSIS OF MYELOID NEOPLASIA PATIENTS

EHA Library, Ana Cristina Gonçalves, 100752

APG101 (SOLUBLE CD95-FC) IMPROVES BFU-E GROWTH IN LOWER RISK MYELODYSPLASTIC SYNDROME WITH COLLAPSED ERYTHROPOIESIS : A PRECLINICAL STUDY.

EHA Library, Michaela Fontenay, 100753

AZACITIDINE IMPROVES THE T-CELL REPERTOIRE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA WITH MULTILINEAGE DYSPLASIA

EHA Library, Claudio Fozza, 100754

REPOPULATING PROGENITOR CELLS IN PRIMARY MDS BONE MARROW CELL CULTURE IN SEVERE HYPOXIC CONDITIONS

EHA Library, Erico Masala, 100755

DIAGNOSTIC UTILITY OF MYELOID NUCLEAR DIFFERENTIATION ANTIGEN EXPRESSION AND OTHER FLOW CYTOMETRIC PARAMETERS IN MYELODYSPLASTIC SYNDROME

EHA Library, Somasundaram Venkatesan, 100756

OVERALL SURVIVAL (OS) AND BASELINE DISEASE CHARACTERISTICS IN MDS PATIENTS WITH PRIMARY HMA FAILURE IN A RANDOMIZED, CONTROLLED, PHASE III STUDY OF RIGOSERTIB

EHA Library, Guillermo Garcia-Manero, 100757

INFERIOR LONG-TERM OUTCOME OF FRONT-LINE HYPOMETHYLATING AGENT COMPARED TO SUPPORTIVE CARE IN PATIENTS WITH LOWER RISK MDS: PROPENSITY SCORE MATCHED ANALYSIS

EHA Library, Joon Ho MOON, 100758

EFFICACY OF CC-486 (ORAL AZACITIDINE) TREATMENT (TX) IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS)

EHA Library, Guillermo Garcia-Manero, 100759

AZACITIDINE (AZA) IN HIGHER RISK MDS PATIENTS WITH CHROMOSOME 7 ABNORMALITIES (ABN 7): RESULTS OF A RETROSPECTIVE STUDY FROM THE GFM AND GESMD REGISTRIES.

EHA Library, María Díez Campelo, 100760

TREATMENT OF HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS) WITH AZACITIDINE: A 4-YEAR POPULATION-BASED ANALYSIS FROM BRITISH COLUMBIA, CANADA

EHA Library, Madeleine Ankenman, 100762

ASSOCIATION OF AZACITIDINE AND LENALIDOMIDE (COMBINATION VS SEQUENTIAL TREATMENT) IN HIGH-RISK MYELODYSPLASTIC SYNDROMES. UPDATE OF THE RESULTS OF A RANDOMIZED PHASE II MULTICENTER STUDY

EHA Library, Carlo Finelli, 100763

CLINICAL IMPACT OF DEL (11Q) IN PATIENTS WITH DE NOVO AND SECONDARY MYELODYSPLASTIC SYNDROMES- A SINGLE INSTITUTION EXPERIENCE

EHA Library, Hassan Alkhateeb, 100764

A PROGNOSTIC MODEL FOR PREDICTING SURVIVAL AFTER STOPPING HYPOMETHYLATING AGENT IN MYELODYSPLASTIC SYNDROME

EHA Library, Hawk Kim, 100765

CORRELATION OF OVERALL SURVIVAL (OS) WITH BONE MARROW BLAST (BMBL) RESPONSE IN PATIENTS (PTS) WITH MYELODYSPLASTIC SYNDROMES (MDS)

EHA Library, Lewis Silverman, 100766

THE INTERIM ANALYSIS OF PROSPECTIVE OBSERVATIONAL STUDY WITH PNH-TYPE CELLS IN JAPANESE PATIENTS WITH BONE MARROW FAILURE (THE OPTIMA STUDY).

EHA Library, Naoshi Obara, 100767

HYPOMEGAKARYOCYTIC THROMBOCYTOPENIA (HMT): AN IMMUNE-MEDIATED BONE MARROW FAILURE CHARACTERIZED BY AN INCREASED NUMBER OF PNH-PHENOTYPE CELLS AND PLASMA THROMBOPOIETIN LEVELS

EHA Library, Ken Ishiyama, 100768

OUTCOME OF STEM CELL TRANSPLANTATION IN PATIENTS WITH SHWACHMAN- DIAMOND SYNDROME WITH OR WITHOUT SECONDARY MDS/AML: AN ANALYSIS OF THE GERMAN SHWACHMAN-DIAMOND SYNDROME COHORT BY THE SCNIR- EUROPE

EHA Library, Sabine Mellor-Heineke, 100769

PEARSON SYNDROME: MULTISYSTEM MITOCHONDRIAL DISORDER WITH BONE MARROW FAILURE

EHA Library, Ayami Yoshimi, 100770

PEARSON SYNDROME: A RETROSPECTIVE COHORT STUDY FROM THE MARROW FAILURE STUDY GROUP OF THE AIEOP (ASSOCIAZIONE ITALIANA EMATO-ONCOLOGIA PEDIATRICA).

EHA Library, Piero Farruggia, 100771

SCREENING OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA CLONES BY MULTICOLOR FLOW CYTOMETRY USING FLUORESCENT AEROLYSIN (FLAER) –A SINGLE CENTRE STUDY OF 212 PATIENTS

EHA Library, Khaliqur Rahman, 100772

LONG TERM OUTCOME OF IMMUNOSUPPRESSIVE THERAPY IN A LARGE COHORT OF 1430 PATIENTS OF APLASTIC ANEMIA FROM A SINGLE TERTIARY CARE CENTRE IN INDIA.

EHA Library, Pawan Kumar Singh, 100773

COMBINED IMMUNOSUPPRESSIVE THERAPY IN PATIENTS WITH APLASTIC ANEMIA WITH REPEATED COURSES OF ATG

EHA Library, Elena Mikhaylova, 100774

PRELIMINARY DATA ON L-LEUCINE THERAPY OF DBA PEDIATRIC PATIENTS

EHA Library, Galina Ovsyannikova, 100775

GENETIC VARIANTS OF COMPLEMENT C5 AND POLYMORPHISMS OF COMPLEMENT C3 IN CHINESE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA.

EHA Library, Bing Han, 100776

EFFECT OF IMID COMPOUNDS ON CD38 EXPRESSION ON MULTIPLE MYELOMA CELLS: MOR202, A HUMAN CD38 ANTIBODY IN COMBINATION WITH POMALIDOMIDE

EHA Library, Rainer Boxhammer, 100777

CENTROSOME ASSOCIATED GENES PATTERN FOR RISK SUBSTRATIFICATION IN MULTIPLE MYELOMA

EHA Library, Katerina Growkova, 100778

BONE MARROW MESENCHYMAL STROMAL CELLS FROM HEALTHY DONORS SECRETE EXOSOMES THAT INHIBIT IN VIVO TUMOR GROWTH AND ANGIOGENESIS IN MULTIPLE MYELOMA

EHA Library, Tomohiro UMEZU, 100779

ANTITUMORAL ACTIVITY OF AMILORIDE IN MULTIPLE MYELOMA THROUGH APOPTOSIS INDUCTION, REGARDLESS OF TP53 MUTATIONAL STATUS

EHA Library, Elizabeta A. Rojas, 100780

BORTEZOMIB-RESISTANCE OF BONE MARROW FIBROBLASTS IN MULTIPLE MYELOMA IS CLOSELY CONNECTED TO ACTIVATION OF AUTOPHAGY AS SURVIVAL MACHINERY

EHA Library, Lucia Di Marzo, 100781

POLYMORPHISMS WITHIN THE CEREBLON AND BETA-CATENIN ENCODING GENES IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Aleksandra Butrym, 100782

A NEW NEXT GENERATION SEQUENCING STRATEGY TO EVALUATE GENETIC ABNORMALITIES IN MULTIPLE MYELOMA

EHA Library, Cristina Jimenez, 100783

HUMAN MYELOMA CELL ENGRAFTMENT IN NEXT GENERATION HUMANIZED MICE EXPRESSING HUMAN INTERLEUKIN 6

EHA Library, Tobias Silzle, 100784

OVEREXPRESSION OF SALIVARY-TYPE AMYLASE REDUCES THE SENSITIVITY TO BORTEZOMIB IN MULTIPLE MYELOMA CELLS

EHA Library, Shohei Mizuno, 100785

A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS OF TREATMENTS FOR PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Katja Weisel, 100786

UPDATED RESULTS FROM A MULTICENTER, OPEN-LABEL, DOSE-ESCALATION PHASE 1B/2 STUDY OF SINGLE-AGENT OPROZOMIB (OPZ) IN PATIENTS (PTS) WITH HEMATOLOGIC MALIGNANCIES, INCLUDING MULTIPLE MYELOMA (MM)

EHA Library, Ravi Vij, 100787

MULTIPLE MYELOMA MANAGEMENT: PRACTICE PATTERNS ACROSS EUROPE

EHA Library, Marc Raab, 100788

MULTIPLE INFUSIONS OF AUTOLOGOUS ACTIVATED AND EXPANDED NATURAL KILLER CELLS: A NEW THERAPEUTIC OPTION FOR MULTIPLE MYELOMA

EHA Library, Alejandra Leivas, 100789

MULTIPLE MYELOMA MANAGEMENT: OUTCOMES IN REAL-WORLD PRACTICE

EHA Library, Kwee Yong, 100790

EUROPEAN POST-APPROVAL SAFETY STUDY (PASS) OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): VTE INCIDENCE, RISK FACTORS, AND USE OF ANTITHROMBOTIC PROPHYLAXIS IN MM PATIENTS TREATED WITH LENALIDOMIDE

EHA Library, Igor Wolfgang Blau, 100791

MANAGEMENT OF ADVERSE EVENTS IN THE STRATUS TRIAL, A PHASE 3B STUDY EVALUATING SAFETY AND EFFICACY OF POMALIDOMIDE+LOW-DOSE DEXAMETHASONE IN REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA

EHA Library, Michele Cavo, 100792

SINGLE CENTER EXPERIENCE WITH EARLY VERSUS LATE AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA

EHA Library, Gergely Varga, 100793

OPROZOMIB (OPZ) AND DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED RESULTS FROM DOSE ESCALATION IN A PHASE 1B/2, MULTICENTER, OPEN-LABEL STUDY

EHA Library, PARAMESWARAN HARI, 100794

PROGNOSTIC IMPACT OF IMMUNOPHENOTYPIC RESPONSE AND NORMALIZATION OF SERUM FREE LIGHT CHAIN AMONG PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Kota Fukumoto, 100795

A PRIOR CANCER DIAGNOSIS IS NOT A RISK FACTOR FOR THE DEVELOPEMENT OF SUBSEQUENT CANCERS IN MULTIPLE MYELOMA PATIENTS

EHA Library, Gudbjörg Jónsdóttir, 100796

MELPHALAN IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE (BMDEX) PRODUCES MORE DURABLE RESPONSES THAN CYCLOPHOSPHAMIDE (CYBORD): A MATCHED CASE-CONTROL STUDY

EHA Library, Paolo Milani, 100797

EVALUATION OF CURRENT CLINICAL MODELS FOR RISK OF PROGRESSION FROM SMOLDERING MULTIPLE MYELOMA TO MULTIPLE MYELOMA IN 287 PATIENTS FOLLOWED IN THE CZECH REPUBLIC

EHA Library, Roman Hájek, 100798

VENETOCLAX (ABT-199/GDC-0199) MONOTHERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE I SAFETY AND EFFICACY

EHA Library, Shaji Kumar, 100799

IMPACT OF FISH ABNORMALITIES ON RISK OF PROGRESSION IN PATIENTS WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE

EHA Library, Shaji Kumar, 100800

POST RELAPSE OUTCOMES IN YOUNG PATIENTS WITH MULTIPLE MYELOMA IN THE ERA OF NOVEL AGENTS

EHA Library, Prashant Kapoor, 100801

SKY92 GEP, IFISH AND ISS COMPARISONS FOR RISK STRATIFICATION IN MULTIPLE MYELOMA

EHA Library, Erik van Beers, 100802

MARKERS OF DISEASE EVOLUTION IN SMOLDERING MULTIPLE MYELOMA (SMM)

EHA Library, Eftychia Nikolaou, 100803

EFFICIENCY AND TOXICITY OF CYCLOPHOSPHAMIDE BASED STEM CELL MOBILIZATION IN RELAPSED MULTIPLE MYELOMA PATIENTS: OBSERVATIONS FROM THE ONGOING PHASE III TRIAL RELAPSE

EHA Library, Marc-A. Baertsch, 100804

HEAVY LIGHT CHAIN RATIO NORMALIZATION ALLOWS IDENTIFICATION OF ELECTROPHORETIC NON-COMPLETE RESPONSE PATIENTS WITH IMPROVED OUTCOMES: A LONG TERM FOLLOW UP UPDATE FOR BMT CTN 0102 CORRELATIVE STUDY.

EHA Library, Anita D'Souza, 100805

CLINICAL IMPACT OF BONE MARROW MORPHOLOGY FOR THE DIAGNOSIS OF ESSENTIAL THROMBOCYTHEMIA: COMPARISON BETWEEN THE BRITISH STANDARDS (BCSH) AND THE WHO CRITERIA

EHA Library, Georg Jeryczynski, 100806

MYELOPROLIFERATIVE NEOPLASMS AND INFECTIONS; A POPULATION-BASED STUDY ON 9,665 PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS DIAGNOSED IN SWEDEN 1987-2009

EHA Library, Malin Hultcrantz, 100807

UNFAVORABLE KARYOTYPE AND MOLECULAR NEGATIVITY SIGNIFICANTLY INFLUENCE THE INFECTIOUS RISK IN MYELOFIBROSIS: EVALUATION ON 426 PATIENTS

EHA Library, Nicola Polverelli, 100808

PRIMARY MYELOFIBROSIS, POST-ET AND POST-PV MYELOFIBROSIS HAVE DISTINCT CLINICAL PROFILES AND SYMPTOMATIC BURDENS: AN ANALYSIS BY THE MPN QUALITY OF LIFE INTERNATIONAL STUDY GROUP (MPN-QOL ISG)

EHA Library, Holly L Geyer, 100809

IMPACT OF CALR AND ASXL1 MUTATIONS ON SURVIVAL AND DISEASE COMPLICATIONS IN ESSENTIAL THROMBOCYTHEMIA AND PREFIBROTIC PRIMARY MYELOFIBROSIS STRICTLY DIAGNOSED ACCORDING TO THE WHO-CLASSIFICATION

EHA Library, Heinz Gisslinger, 100810

RUXOLITINIB PROVIDES CONSISTENT HEMATOCRIT CONTROL IN PATIENTS WITH POLYCYTHEMIA VERA (PV) RESISTANT TO OR INTOLERANT OF HYDROXYUREA

EHA Library, Martin Griesshammer, 100811

PHASE 2 STUDY OF A NOVEL CONTROLLED-RELEASE FORMULATION OF ANAGRELIDE (GALE-401) IN SUBJECTS WITH MYELOPROLIFERATIVE NEOPLASM (MPN)-RELATED THROMBOCYTOSIS

EHA Library, Nasiema Wingate-Pearse, 100812

SAFETY OF RUXOLITINIB IN PATIENTS WITH POLYCYTHEMIA VERA: RESULTS FROM THE CLINICAL TRIAL PROGRAM

EHA Library, Srdan Verstovsek, 100813

EFFECT OF RUXOLITINIB ON MARKERS OF IRON DEFICIENCY: AN ANALYSIS OF THE RESPONSE TRIAL

EHA Library, Srdan Verstovsek, 100814

RUXOLITINIB REDUCES JAK2P.V617F ALLELE BURDEN IN PATIENTS WITH MYELOFIBROSIS

EHA Library, Srdan Verstovsek, 100815

SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS WITH INTERMEDIATE-1–RISK MYELOFIBROSIS (MF) FROM AN OPEN-LABEL, MULTICENTER, SINGLE-ARM EXPANDED-ACCESS STUDY

EHA Library, Pilar Giraldo Castellano, 100816

INTERIM ANALYSIS OF A PHASE II PILOT TRIAL OF RUXOLITINIB COMBINED WITH DANAZOL FOR PATIENTS WITH MYELOFIBROSIS SUFFERING FROM ANEMIA

EHA Library, Ruben Mesa, 100817

BONE MARROW FIBROSIS BY WHO GRADE AND QUANTITATIVE IMAGE ANALYSIS IS REDUCED BY PRM-151 IN PATIENTS WITH MYELOFIBROSIS AND ASSOCIATED WITH IMPROVED BONE MARROW MORPHOLOGY AND INCREASED PLATELET COUNTS

EHA Library, Olga Pozdnyakova, 100818

THE ITALIAN MASTOCYTOSIS REGISTRY: THE FIRST FIVE YEARS

EHA Library, Serena Merante, 100819

HIGH RATE OF DISCORDANCY REGARDING DIAGNOSIS AND SUBCLASSIFICATIONOF SYSTEMIC MASTOCYTOSIS ON BONE MARROW BIOPSIESBETWEEN INITIAL LOCAL AND CENTRALIZED REFERENCE HEMATOPATHOLOGY

EHA Library, Mohamad Jawhar, 100820

CLINICAL AND MOLECULAR CHARACTERISTICS OF PATIENTS WITH SYSTEMIC MASTOCYTOSIS AND ASSOCIATED ACUTE MYELOID LEUKAEMIA

EHA Library, Sebastian Kreil, 100821

VALIDATION OF THE SIMPLIFIED PROGNOSTIC SCORE FOR SMZL OF THE SMZLSG (SMZL STUDY GROUP) IN A SERIES OF PATIENTS TREATED WITH RITUXIMAB MONOTHERAPY, AND LONG TERM OUTCOME OF RITUXIMAB RESPONDERS

EHA Library, Christina Kalpadakis, 100822

INCIDENCE OF TRANSFORMATION IN FOLLICULAR LYMPHOMA: MULTICENTRE RETROSPECTIVE ANALYSIS OF THE SPANISH GROUP OF LYMPHOMA AND AUTOLOGOUS STEM-CELL TRANSPLANTATION (GELTAMO)

EHA Library, Miguel Alcoceba, 100823

PROSPECTIVELY DEFINED TRIAL- (N=13) AND PATIENT- (N=3837) LEVEL ANALYSIS OF COMPLETE RESPONSE RATES AS SURROGATE ENDPOINTS FOR PROGRESSION-FREE SURVIVAL (PFS) IN FIRST-LINE FOLLICULAR LYMPHOMA (FL)

EHA Library, Daniel Sargent, 100824

MYD-88 L265P IN A SERIES OF CD5(-) CLONAL B-CELL LYMPHOCYTOSIS OF MARGINAL ZONE ORIGIN (CD5- CBL)

EHA Library, Christina Kalpadakis, 100825

EFFICACY AND SAFETY OF R-COMP REGIMEN IN NON HODGKIN LYMPHOMA PATIENTS WITH CARDIOVASCULAR COMORBIDITIES.

EHA Library, Ombretta Annibali, 100826

THE EFFECTIVENESS OF ANTIVIRAL THERAPY IN PATIENTS WITH HEPATITIS C ASSOCIATED INDOLENT LYMPHOMA (IL + C)

EHA Library, sergey lepkov, 100827

COMPARISON OF SUBCUTANEOUS AND INTRAVENOUS RITUXIMAB IN THE MAINTENANCE SETTING: UPDATED SAFETY RESULTS OF THE PHASE III SABRINA STUDY IN PATIENTS WITH FOLLICULAR LYMPHOMA

EHA Library, Andrew J. Davies, 100828

TWO DOSES OF POLATUZUMAB VEDOTIN (POV, ANTI-CD79B ANTIBODY-DRUG CONJUGATE) PLUS RITUXIMAB (R) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): DURABLE RESPONSES AT LOWER DOSE LEVEL

EHA Library, Jeff Sharman, 100829

IDELALISIB EFFICACY AND SAFETY IN FOLLICULAR LYMPHOMA PATIENTS FROM A PHASE 2 STUDY

EHA Library, Pier Luigi Zinzani, 100830

IDELALISIB MONOTHERAPY RESULTS IN DURABLE RESPONSES IN PATIENTS WITH RELAPSED OR REFRACTORY WALDENSTROM’S MACROGLOBULINEMIA (WM)

EHA Library, Steven E Coutre, 100831

RECURRENT TP53 ALTERATIONS IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA RELAPSING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

EHA Library, Jessica Hoell, 100832

MESENCHYMAL STROMAL CELLS STIMULATE PROLIFERATION AND CYTOKINE PRODUCTION OF GROUP 3 INNATE LYMPHOID CELLS

EHA Library, Marius Munneke, 100833